Top

Published in:

Open Access 01-05-2013 | Vascular Biology (RS Rosenson, Section Editor)

GPR109A and Vascular Inflammation

Authors: Joshua T. Chai, Janet E. Digby, Robin P. Choudhury

Published in: Current Atherosclerosis Reports | Issue 5/2013

Abstract

GPR109A has generated expanding interest since its discovery as the receptor for niacin a decade ago, along with deorphanisation as the receptor for endogenous ligand 3-hydroxy-butyrate shortly after. This interest is generated especially because of the continuing exploration of niacin’s “pleiotropic” mechanisms of action and its potential in the “cross-talk” between metabolic and inflammatory pathways. As GPR109A’s primary pharmacological ligand in clinical use, niacin has been used for over 50 years in the treatment of cardiovascular disease, mainly due to its favourable effects on plasma lipoproteins. However, it has become apparent that niacin also possesses lipoprotein-independent effects that influence inflammatory pathways mediated through GPR109A. In addition to its G-protein–mediated effects, recent evidence has emerged to support alternative GPR109A signalling via adaptive protein β-arrestins. In this article, we consider the role of GPR109A and its downstream effects in the context of atherosclerosis and vascular inflammation, along with insights into strategy for future drug development.

• Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, Ijzerman AP. International union of basic and clinical pharmacology. Lxxxii: nomenclature and classification of hydroxy-carboxylic acid receptors (gpr81, gpr109a, and gpr109b). Pharmacol Rev. 2011;63:269–90. This review comprehensively discussed the discovery of HCA family of receptors, their putative biological roles, as well as development of pharmaceutical agents to target GPR109A, GPR109B, and GPR81. PubMedCrossRef

Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54:558–9.PubMedCrossRef

Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun. 2003;303:364–9.PubMedCrossRef

Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. Puma-g and hm74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003;9:352–5.PubMedCrossRef

Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278:9869–74.PubMedCrossRef

Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, et al. (d)-beta-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor puma-g. J Biol Chem. 2005;280:26649–52.PubMedCrossRef

Cai TQ, Ren N, Jin L, Cheng K, Kash S, Chen R, et al. Role of gpr81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun. 2008;377:987–91.PubMedCrossRef

Ahmed K, Tunaru S, Langhans CD, Hanson J, Michalski CW, Kolker S, et al. Deorphanization of gpr109b as a receptor for the beta-oxidation intermediate 3-oh-octanoic acid and its role in the regulation of lipolysis. J Biol Chem. 2009;284:21928–33.PubMedCrossRef

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.PubMedCrossRef

10.

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRef

11.

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the ideal study: a randomized controlled trial. JAMA. 2005;294:2437–45.PubMedCrossRef

12.

Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective american studies. Circulation. 1989;79:8–15.PubMedCrossRef

13.

Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16–9.PubMedCrossRef

14.

Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30:1430–8.PubMedCrossRef

15.

Rosenson RS, Brewer Jr HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905–19.PubMedCrossRef

16.

Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med. 2005;2:309–15.PubMedCrossRef

17.

Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Inflamm. 2011;8:9.CrossRef

18.

Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.PubMedCrossRef

19.

Hewing B, Fisher EA. Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. Expert Opin Drug Discov. 2012;7:207–16.PubMedCrossRef

20.

Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, rantes, and mcp-1 and upregulation of adiponectin. Atherosclerosis. 2010;209:89–95.PubMedCrossRef

21.

Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai JT, Wamil M, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by gpr109a dependent mechanisms. Arterioscler Thromb Vasc Biol. 2012;32:669–76.PubMedCrossRef

22.

Kamanna VS, Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep. 2000;2:36–46.PubMedCrossRef

23.

Peterson MJ, Hillman CC, Ashmore J. Nicotinic acid: studies on the mechamism of its antilipolytic action. Mol Pharmacol. 1968;4:1–9.PubMed

24.

Yousefi S, Cooper PR, Mueck B, Potter SL, Jarai G. Cdna representational difference analysis of human neutrophils stimulated by gm-csf. Biochem Biophys Res Commun. 2000;277:401–9.PubMedCrossRef

25.

Schaub A, Futterer A, Pfeffer K. Puma-g, an ifn-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur J Immunol. 2001;31:3714–25.PubMedCrossRef

26.

Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen B, Ahmed K, et al. Nicotinic acid and monomethyl fumarate induced flushing involves gpr109a expressed by keratinocytes and cox-2 dependent prostanoid formation in mice. J Clin Investig. 2010;120:2910–9.PubMedCrossRef

27.

Zhang Y, Schmidt RJ, Foxworthy P, Emkey R, Oler JK, Large TH, et al. Niacin mediates lipolysis in adipose tissue through its g-protein coupled receptor hm74a. Biochem Biophys Res Commun. 2005;334:729–32.PubMedCrossRef

28.

Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr Opin Lipidol. 2009;20:321–6.PubMedCrossRef

29.

•• Lauring B, Taggart AKP, Tata JR, Dunbar R, Caro L, Cheng K, et al. Niacin lipid efficacy is independent of both the niacin receptor gpr109a and free fatty acid suppression. Sci Transl Med. 2012;4:148ra115–148ra115. This fascinating study first used a genetic, humanised, mouse model to show that the effect of niacin on FFA lipolysis is dependent on GPR109A but its effect of plasma lipoprotein is not. The authors then went on to show that selective GPR109A agonists can inhibit FAA release but has no effect on plasma lipoprotein. To confirm applicability in human subjects, the authors conducted separate human trials to show that selective GPR109A agonists, while reducing plasma FAA, did not exhibit anticipated effect on plasma lipoprotein; hence refuting the previous “FFA hypothesis” regarding niacin’s mechanism of action. PubMedCrossRef

30.

Offermanns S. It ain’t over 'til the fat lady sings. Sci Transl Med. 2012;4:148fs130.CrossRef

31.

Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apob degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (hepg2) cells. Arterioscler Thromb Vasc Biol. 1999;19:1051–9.PubMedCrossRef

32.

Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of atp synthase beta chain in hepg2 cells: implications for raising hdl. J Lipid Res. 2008;49:1195–201.PubMedCrossRef

33.

Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits dgat2 but not dgat1 activity in hepg2 cells. J Lipid Res. 2004;45:1835–45.PubMedCrossRef

34.

Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, et al. Identification of a gene encoding an acyl coa:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A. 1998;95:13018–23.PubMedCrossRef

35.

Chung S, Sawyer JK, Gebre AK, Maeda N, Parks JS. Adipose tissue ATP binding cassette transporter A1 contributes to high-density lipoprotein biogenesis in vivo. Circulation. 2011;124(15):1663–72.

36.

Wu Z-H, Zhao S-P. Niacin promotes cholesterol efflux through stimulation of the pparγ-lxrα-abca1 pathway in 3t3-l1 adipocytes. Pharmacology. 2009;84:282–7.PubMedCrossRef

37.

Knowles H, Poole R, Workman P, Harris A. Niacin induces pparγ expression and transcriptional activation in macrophages via hm74 and hm74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol. 2006;71:646–56.PubMedCrossRef

38.

Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039–46.PubMedCrossRef

39.

Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol. 1995;15:1987–94.PubMedCrossRef

40.

Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, et al. Inhibition of vcam-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun. 1997;238:61–5.PubMedCrossRef

41.

Park SH, Park JH, Kang JS, Kang YH. Involvement of transcription factors in plasma hdl protection against tnf-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol. 2003;35:168–82.PubMedCrossRef

42.

Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR. High density lipoproteins (hdl) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by hdl. J Biol Chem. 1999;274:33143–7.PubMedCrossRef

43.

Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of hdl. Circ Res. 2004;95:764–72.PubMedCrossRef

44.

Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of e-selectin in an in vivo model of acute inflammation. Circulation. 2001;103:108–12.PubMedCrossRef

45.

Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30:968–75.PubMedCrossRef

46.

Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003;107:2944–8.PubMedCrossRef

47.

Warnholtz A, Wild P, Ostad MA, Elsner V, Stieber F, Schinzel R, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled inef study. Atherosclerosis. 2009;204:216–21.PubMedCrossRef

48.

•• Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor gpr109a expressed by immune cells. J Clin Investig. 2011;121:1163–73. This elegant study showed that niacin reduces progression of atherosclerosis in a mouse model independent of its lipoprotein effect. Importantly, this anti-atherosclerotic effect of niacin is dependent on the expression of GPR109A in myeloid cells and that bone-marrow transplantation of GPR109A-deficient myeloid cells abrogated the beneficial effect of niacin. This convincingly illustrated that GPR109A mediates the anti-inflammatory effect of niacin independent of its effect on plasma lipoprotein. PubMedCrossRef

49.

Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202:68–75.PubMedCrossRef

50.

Lukasova M, Hanson J, Tunaru S, Offermanns S. Nicotinic acid (niacin): New lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol Sci. 2011;32(12):700–7.

51.

Digby JE, Martinez FO, Jefferson A, Ruparelia N, Wamil M, Greaves DR, Choudhury RP. Anti-inflammatory effects of nicotnic acid: Mechanisms of action in human monocytes. Circ Suppl. 2011;124:A14830.

52.

Tavintharan S, Lim SC, Sum CF. Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic Clin Pharmacol Toxicol. 2009;104:206–10.PubMedCrossRef

53.

Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74:213–20.PubMedCrossRef

54.

Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ ccr2, ccr5, and cx3cr1 to accumulate within atherosclerotic plaques. J Clin Invest. 2007;117:185–94.PubMedCrossRef

55.

Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res. 2004;95:858–66.PubMedCrossRef

56.

Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter abca1 functions as an anti-inflammatory receptor. J Biol Chem. 2009;284:32336–43.PubMedCrossRef

57.

Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, et al. Macrophage abca1 reduces myd88-dependent toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res. 2010;51:3196–206.PubMedCrossRef

58.

Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, et al. Atp-binding cassette transporters and hdl suppress hematopoietic stem cell proliferation. Science. 2010;328:1689–93.PubMedCrossRef

59.

Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506–16.PubMedCrossRef

60.

Lee JMS, Robson MD, Yu L-M, Shirodaria CC, Cunnington C, Kylintireas I, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular functiona randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787–94.PubMedCrossRef

61.

Krupnick JG, Benovic JL. The role of receptor kinases and arrestins in g protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol. 1998;38:289–319.PubMedCrossRef

62.

Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. Beta-arrestin: a protein that regulates beta-adrenergic receptor function. Science. 1990;248:1547–50.PubMedCrossRef

63.

Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, et al. Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem. 1992;267:17882–90.PubMed

64.

• Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM, et al. Β-arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice. J Clin Investig. 2009;119:1312–21. This study beautifully dissected the role of G-protein versus β-arrestin signalling downstream of GPR109A activation by niacin. It demonstrated that while its therapeutic effect on FFA release may be mediated through the classic G-protein cascade, the side-effect of cutaneous flushing can be dissociated as they are mediated by an alternative signalling pathway via β-arrestins. The implication of this ‘biased agonism’ may be exploited in guiding future drug development. PubMedCrossRef

65.

Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B, et al. Identification of beta-arrestin2 as a g protein-coupled receptor stimulated regulator of nf-kb pathways. Mol Cell. 2004;14:303–17.PubMedCrossRef

66.

Witherow DS. β-arrestin inhibits nf- b activity by means of its interaction with the nf- b inhibitor i b. Proc Natl Acad Sci. 2004;101:8603–7.PubMedCrossRef

67.

Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of β-arrestin1 in gpcr signaling: regulation of histone acetylation and gene transcription. Cell. 2005;123:833–47.PubMedCrossRef

68.

Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, et al. Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem. 2007;282:18028–36.PubMedCrossRef

69.

Lai E, Waters MG, Tata JR, Radziszewski W, Perevozskaya I, Zheng W, et al. Effects of a niacin receptor partial agonist, mk-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol. 2008;2:375–83.PubMedCrossRef

70.

Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, Cherrier MC, et al. 3-(1h-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (mk-0354): a partial agonist of the nicotinic acid receptor, g-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem. 2008;51:5101–8.PubMedCrossRef

71.

Senior B, Loridan L. Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man. Nature. 1968;219:83–4.PubMedCrossRef

72.

Offermanns S. The nicotinic acid receptor gpr109a (hm74a or puma-g) as a new therapeutic target. Trends Pharmacol Sci. 2006;27:384–90.PubMedCrossRef

73.

Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov. 2012;11:603–19.PubMedCrossRef

74.

Wanders D, Graff EC, Judd RL. Effects of high fat diet on gpr109a and gpr81 gene expression. Biochem Biophys Res Commun. 2012;425:278–83.PubMedCrossRef

75.

Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, et al. Butyrate suppresses colonic inflammation through hdac1-dependent fas upregulation and fas-mediated apoptosis of t cells. Am J Physiol Gastrointest Liver Physiol. 2012;302:G1405–15.PubMedCrossRef

76.

Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. Gpr109a is a g-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009;69:2826–32.PubMedCrossRef

77.

Masuda R, Monahan JW, Kashiwaya Y. D-beta-hydroxybutyrate is neuroprotective against hypoxia in serum-free hippocampal primary cultures. J Neurosci Res. 2005;80:501–9.PubMedCrossRef

78.

Prins ML, Lee SM, Fujima LS, Hovda DA. Increased cerebral uptake and oxidation of exogenous betahb improves atp following traumatic brain injury in adult rats. J Neurochem. 2004;90:666–72.PubMedCrossRef

79.

Samoilova M, Weisspapir M, Abdelmalik P, Velumian AA, Carlen PL. Chronic in vitro ketosis is neuroprotective but not anti-convulsant. J Neurochem. 2010;113:826–35.PubMedCrossRef

80.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral bg-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.PubMedCrossRef

81.

Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013–7.PubMedCrossRef

82.

Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.PubMedCrossRef

83.

Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The arbiter 6-halts trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-hdl and ldl treatment strategies in atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721–6.PubMedCrossRef

84.

Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (arbiter) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–7.PubMedCrossRef

85.

Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: Arbiter 3. Curr Med Res Opin. 2006;22:2243–50.PubMedCrossRef

86.

Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22.PubMedCrossRef

87.

Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012;32:582–8.PubMedCrossRef

88.

Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–61.PubMedCrossRef

89.

Lavigne PM, Karas R. The role of niacin in the aftermath of aim-high: a meta-analysis. J Am Coll Cardiol. 2012;59:E1687.CrossRef

90.

Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low hdl cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.PubMedCrossRef

91.

Nicholls SJ. The aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) trial: to believe or not to believe? J Am Coll Cardiol. 2012;59:2065–7.PubMedCrossRef

92.

Rosenson RS. Clinical trials of hdl cholesterol-raising therapy: what have we learned about the hdl hypothesis from aim-high? Curr Atheroscler Rep. 2012;14:190–2.PubMedCrossRef

93.

Hps2-thrive: A randomized trial of the long-term clinical effects of raising hdl cholesterol with extended release niacin/laropiprant. Http://www.Thrivestudy.Org.

94.

Merck news release “merck announces hps2-thrive study of tredaptive (extended release niacin/laropiprant) did not achieve primary endpoint” released 20th december 2012.

95.

European medicines agency confirmes recommendation to suspend tredaptive, pelzont and trevaclyn. Press release 18th january 2013. European medicines agency.

96.

Shen HC, Colletti SL. Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opin Ther Pat. 2009;19:957–67.PubMedCrossRef

97.

Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, et al. Discovery of the first potent and orally efficacious agonist of the orphan g-protein coupled receptor 119. J Med Chem. 2008;51:5172–5.PubMedCrossRef

98.

Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov. 2008;7:517–29.PubMedCrossRef

99.

Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. Carotid plaque inflammation on (18) f-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012;71:709–18.PubMedCrossRef

100.

Li G, Shi Y, Huang H, Zhang Y, Wu K, Luo J, et al. Internalization of the human nicotinic acid receptor gpr109a is regulated by gi, grk2, and arrestin3. J Biol Chem. 2010;285:22605–18.PubMedCrossRef

101.

Prusty D, Park B-H, Davis KE, Farmer SR. Activation of mek/erk signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma and c/ebp alpha gene expression during differentiation of 3t3-l1 preadipocytes. J Biol Chem. 2002;277:46226–32.PubMedCrossRef

102.

Chawla A, Boisvert WA, Lee C-H, Laffitte BA, Barak Y, Joseph SB, et al. A pparg-lxr-abca1 pathway in macrophages in involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161–71.PubMedCrossRef

103.

Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. Ppar-α and ppar-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the abca1 pathway. Nat Med. 2001;7:53–8.PubMedCrossRef

Title: GPR109A and Vascular Inflammation
Authors: Joshua T. Chai
Janet E. Digby
Robin P. Choudhury
Publication date: 01-05-2013
Publisher: Current Science Inc.
Published in: Current Atherosclerosis Reports / Issue 5/2013
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-013-0325-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield

Modulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular Inflammation

Epigenetic Regulation of Vascular Smooth Muscle Cell Function in Atherosclerosis

Polyphenols, Inflammation, and Cardiovascular Disease

Oxidized PLs and Vascular Inflammation

MicroRNAs and Atherosclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials